Project Details
Description
The objective of this proposal is to develop a new paradigm for Lipiodol TACE. An innovative anti-angiogenic drug-eluting microsphere platform will serve as the embolic material used during conventional TACE methods (involving Lipiodol + Doxorubicin) to enhance therapeutic outcomes. We will optimize the synthesis protocols for these sorafenib-eluting embolic microspheres and ultimately validate that the Lipiodol TACE + sorafenib-eluting embolic microsphere method permits superior outcomes in an orthotropic rodent HCC model.
| Status | Finished |
|---|---|
| Effective start/end date | 11/1/16 → 11/1/19 |
Funding
- Guerbet LLC (Agmt 11/01/16)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.